Clinical Report: Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

Overview

VIVEbiotech and Zelluna are collaborating on GMP lentiviral vector manufacturing for TCR-NK cell therapies targeting solid tumors. The partnership has been ongoing since 2018, with clinical trials for their lead candidate, ZI-MA4-1, planned for 2026.

Background

The development of allogeneic cell therapies, particularly for solid tumors, presents significant manufacturing challenges, including the need for high purity and consistent quality of lentiviral vectors. These challenges are critical as they impact the manufacturing process of off-the-shelf therapies, which are designed to be readily available for multiple patients.

Data Highlights

No numerical data available in the source material.

Key Findings

• The collaboration between VIVEbiotech and Zelluna has been ongoing since 2018.
• ZI-MA4-1, Zelluna's lead candidate, targets MAGE-A4 and is set to enter clinical trials in 2026.
• Manufacturing lentiviral vectors requires achieving high purity, consistent quality, and scalability.
• Higher-performing lentiviral vectors enable efficient gene transfer, improving safety profiles.
• Advances in gene and cell therapy technologies are creating new opportunities for treating solid tumors.
• Automation and streamlined quality control are essential for making off-the-shelf therapies more accessible.

Clinical Implications

The collaboration focuses on enhancing the manufacturing processes necessary for the development of TCR-NK cell therapies.

Conclusion

The partnership between VIVEbiotech and Zelluna addresses manufacturing challenges in the development of TCR-NK cell therapies for solid tumors.

Related Resources & Content

1. VIVEbiotech, Zelluna, 2023 -- Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy
2. Frontiers in Immunology — Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation
3. The ASCO Post — CAR T-Cell Therapy Makes Further Inroads in Lymphoma and Myeloma
4. The ASCO Post — Expert Point of View: Jane N. Winter, MD
5. The ASCO Post — Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
6. TECELRA | FDA
7. Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
8. Cellular & Gene Therapy Guidances | FDA